Brian F. Clem

3.8k total citations
52 papers, 2.8k citations indexed

About

Brian F. Clem is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Brian F. Clem has authored 52 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Molecular Biology, 36 papers in Cancer Research and 27 papers in Oncology. Recurrent topics in Brian F. Clem's work include Cancer, Hypoxia, and Metabolism (32 papers), Cancer-related Molecular Pathways (22 papers) and Metabolism, Diabetes, and Cancer (12 papers). Brian F. Clem is often cited by papers focused on Cancer, Hypoxia, and Metabolism (32 papers), Cancer-related Molecular Pathways (22 papers) and Metabolism, Diabetes, and Cancer (12 papers). Brian F. Clem collaborates with scholars based in United States, Türkiye and Spain. Brian F. Clem's co-authors include Jason Chesney, Sucheta Telang, Abdullah Yalçın, Amy Clem, Andrew N. Lane, Julie O’Neal, John O. Trent, Alden C. Klarer, Yoannis Imbert-Fernandez and Sengodagounder Arumugam and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Brian F. Clem

50 papers receiving 2.8k citations

Peers

Brian F. Clem
Wenjing Du China
Sumin Kang United States
Aaron M. Hosios United States
Naoharu Takano Japan
Paulo A. Gameiro United States
Hongxia Hu China
Laura V. Danai United States
Elke Markert United Kingdom
Xiaohu Tang United States
Chenfang Dong China
Wenjing Du China
Brian F. Clem
Citations per year, relative to Brian F. Clem Brian F. Clem (= 1×) peers Wenjing Du

Countries citing papers authored by Brian F. Clem

Since Specialization
Citations

This map shows the geographic impact of Brian F. Clem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian F. Clem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian F. Clem more than expected).

Fields of papers citing papers by Brian F. Clem

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian F. Clem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian F. Clem. The network helps show where Brian F. Clem may publish in the future.

Co-authorship network of co-authors of Brian F. Clem

This figure shows the co-authorship network connecting the top 25 collaborators of Brian F. Clem. A scholar is included among the top collaborators of Brian F. Clem based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian F. Clem. Brian F. Clem is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Marshall, Erin A., Avery J. C. Noonan, Fernando Sergio Leitão Filho, et al.. (2023). Methionine-producing tumor micro(be) environment fuels growth of solid tumors. Cellular Oncology. 46(6). 1659–1673. 10 indexed citations
2.
Petri, Belinda J., Kellianne M. Piell, Norman L. Lehman, et al.. (2021). HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells. Cancer Letters. 518. 152–168. 39 indexed citations
3.
Petri, Belinda J., Traci Kruer, Benjamin Green, et al.. (2020). Serine synthesis influences tamoxifen response in ER+ human breast carcinoma. Endocrine Related Cancer. 28(1). 27–37. 17 indexed citations
4.
Conroy, Lindsey R., Pawel Lorkiewicz, Liqing He, et al.. (2020). Palbociclib treatment alters nucleotide biosynthesis and glutamine dependency in A549 cells. Cancer Cell International. 20(1). 280–280. 12 indexed citations
5.
Dougherty, Susan, et al.. (2019). Selective loss of phosphoserine aminotransferase 1 (PSAT1) suppresses migration, invasion, and experimental metastasis in triple negative breast cancer. Clinical & Experimental Metastasis. 37(1). 187–197. 42 indexed citations
6.
Lorkiewicz, Pawel, Andrew Gibb, Liqing He, et al.. (2019). Integration of flux measurements and pharmacological controls to optimize stable isotope-resolved metabolomics workflows and interpretation. Scientific Reports. 9(1). 13705–13705. 19 indexed citations
7.
Clem, Brian F.. (2014). RB in glutamine metabolism. Oncoscience. 1(5). 304–305. 2 indexed citations
8.
Liu, Yongqing, Xiaoqin Lu, Li Huang, et al.. (2014). Different thresholds of ZEB1 are required for Ras-mediated tumour initiation and metastasis. Nature Communications. 5(1). 5660–5660. 59 indexed citations
9.
Liu, Yongqing, Ester Sànchez‐Tilló, Xiaoqin Lu, et al.. (2013). Sequential Inductions of the ZEB1 Transcription Factor Caused by Mutation of Rb and Then Ras Proteins Are Required for Tumor Initiation and Progression. Journal of Biological Chemistry. 288(16). 11572–11580. 28 indexed citations
10.
Liu, Yongqing, Ester Sànchez‐Tilló, Xiaoqin Lu, et al.. (2013). The ZEB1 Transcription Factor Acts in a Negative Feedback Loop with miR200 Downstream of Ras and Rb1 to Regulate Bmi1 Expression. Journal of Biological Chemistry. 289(7). 4116–4125. 35 indexed citations
11.
Lane, Andrew N., Brita Robertson, Yaping Liu, et al.. (2013). Control of glutamine metabolism by the tumor suppressor Rb. Oncogene. 33(5). 556–566. 178 indexed citations
12.
Liu, Yongqing, Ester Sànchez‐Tilló, Xiaoqin Lu, et al.. (2013). Rb1 family mutation is sufficient for sarcoma initiation. Nature Communications. 4(1). 2650–2650. 23 indexed citations
13.
Telang, Sucheta, Kristin K. Nelson, Deanna Siow, et al.. (2012). Cytochrome c oxidase is activated by the oncoprotein Ras and is required for A549 lung adenocarcinoma growth. Molecular Cancer. 11(1). 60–60. 17 indexed citations
14.
Telang, Sucheta, Brian F. Clem, Alden C. Klarer, et al.. (2012). Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activation. Journal of Translational Medicine. 10(1). 95–95. 76 indexed citations
15.
Clem, Brian F., Amy Clem, Abdullah Yalçın, et al.. (2011). A novel small molecule antagonist of choline kinase-α that simultaneously suppresses MAPK and PI3K/AKT signaling. Oncogene. 30(30). 3370–3380. 62 indexed citations
16.
Clem, Brian F., et al.. (2011). Block Copolymer Micelles for Controlled Delivery of Glycolytic Enzyme Inhibitors. Pharmaceutical Research. 29(3). 847–855. 19 indexed citations
17.
Yalçın, Abdullah, Brian F. Clem, Alan J. Simmons, et al.. (2009). Nuclear Targeting of 6-Phosphofructo-2-kinase (PFKFB3) Increases Proliferation via Cyclin-dependent Kinases. Journal of Biological Chemistry. 284(36). 24223–24232. 188 indexed citations
18.
Yalçın, Abdullah, Brian F. Clem, Amy Clem, et al.. (2009). Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling. Oncogene. 29(1). 139–149. 82 indexed citations
19.
Yalçın, Abdullah, Sucheta Telang, Brian F. Clem, & Jason Chesney. (2009). Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. Experimental and Molecular Pathology. 86(3). 174–179. 306 indexed citations
20.
Liu, Yongqing, Brian F. Clem, Ewa Zuba‐Surma, et al.. (2009). Mouse Fibroblasts Lacking RB1 Function Form Spheres and Undergo Reprogramming to a Cancer Stem Cell Phenotype. Cell stem cell. 4(4). 336–347. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wenjing Du Breakdown of academic impact, for papers by Sumin Kang Breakdown of academic impact, for papers by Aaron M. Hosios Breakdown of academic impact, for papers by Naoharu Takano Breakdown of academic impact, for papers by Paulo A. Gameiro Breakdown of academic impact, for papers by Hongxia Hu Breakdown of academic impact, for papers by Laura V. Danai Breakdown of academic impact, for papers by Elke Markert Breakdown of academic impact, for papers by Xiaohu Tang Breakdown of academic impact, for papers by Chenfang Dong
Rankless by CCL
2026